Patient Characteristics
| Restaging | |||||||
| Characteristic | Initial staging: treatment-naïve | After ADT | After surgery, PSA < 0.2 | After RT, PSA < nadir + 2 | Other primary treatment | Advanced disease | Full cohort |
| Number of patients | 30 (15%) | 16(8%) | 13(7%) | 22(11%) | 13(6%) | 103(52%) | 197 |
| Mean age (y) | 69.70 ± 7.02 (51–85) | 64.38 ± 9.53 (49–82) | 68.85 ± 8.73 (47–76) | 69.82 ± 8.06 (56–86) | 63.85 ± 8.86 (49–77) | 69.72 ± 8.61 (46–95) | 68.52 ± 8.64 (46–95) |
| Mean PSA at time of PET ( ng/mL) | 19.43 ± 27.58 (2.4–135.50) | 62.48 ± 100.36 (0.17–322) | 0.13 ± 0.05 (0.04–0.2) | 1.79 ± 1.31 (0.3–5.6) | 11.53 ± 19.65 (1.10–74.30) | 40.66 ± 188.04 (0.02–1,789) | 30.03 ± 139.95 (0.02 –1,789) |
| PSA (ng/mL) at time of PSMA PET* | t2 to ≤5: 6 | 0 to ≤0.2: 1 | 0 to ≤0.2: 13 | 0 to ≤0.2: 0 | 0 to ≤0.2: 0 | 0 to ≤0.2: 10 | 0 to ≤0.2: 24 |
| 5 to ≤10: 11 | 0.2 to ≤0.5: 2 | 0.2 to ≤0.5: 0 | 0.2 to ≤0.5: 3 | 0.2 to ≤0.5: 0 | 0.2 to ≤0.5: 16 | 0.2 to ≤0.5: 21 | |
| 10 to ≤20: 5 | 0.5 to ≤2: 2 | 0.5 to ≤2: 0 | 0.5 to ≤2: 10 | 0.5 to ≤2: 1 | 0.5 to ≤2: 25 | 0.5 to ≤2: 38 | |
| >20: 8 | >2: 11 | >2: 0 | >2: 9 | >2: 12 | >2: 52 | >2: 114 | |
| Currently under ADT | 0 | 16 (100%) | 4 (13%) | 5 (20%) | 0 | 37 (43%) | 59 (30%) |
| Gleason score | ≤: 19 | ≤7: 4 | ≤7: 8 | ≤7: 12 | ≤7: 7 | ≤7: 41 | ≤7: 91 |
| ≥8: 11 | ≥8: 10 | ≥8: 4 | ≥8: 6 | ≥8: 3 | ≥8: 45 | ≥8: 79 | |
| Unknown: 0 | Unknown: 2 | Unknown: 1 | Unknown: 4 | Unknown: 3 | Unknown: 17 | Unknown: 27 | |
↵* Serum PSA ranges used for treatment-naïve group are different from other groups.
ADT = androgen deprivation therapy; known M1 = known metastatic disease.
Qualitative data are expressed as number followed by percentage in parentheses; continuous data are expressed as mean ± SD followed by range in parentheses.